Love & Joy Family Clinic announced an expansion of its screening offerings that strengthens the practice's cancer screenin ...

Author:Shweta Raskar, Business Development Specialist, Prophecy Market InsightsIntroductionThe Multi-Cancer Early Detection (MCED) Market is witnessing an unprecedented surge as diagnostic ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

In a pioneering collaboration aimed at transforming pediatric cancer diagnostics and research, Dana-Farber Cancer Institute, ...

According to MarketsandMarkets™, The seed technologies market is projected to reach USD 14.50 billion by 2030 from USD 9.35 billion in 2025, ...

Early diagnosis of vaping-related lung injury and immediate cessation, along with antibiotics and steroids, can often reverse ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.